

Description

The PRAME Peptide (432-440, GLSNLTHVL) is a peptide corresponding to PRAME (Preferentially Expressed Antigen in Melanoma), amino acids 432-440. The PRAME peptide is widely used to stimulate human PRAME-specific CD8⁺ T cells.

Background

PRAME (Preferentially Expressed Antigen in Melanoma) is a protein with a profile of expression in normal tissues highly restricted to testis, ovary, and endometrium. However, it is found at high levels in several cancer types, such as melanoma, breast, and lung cancer. It is also found in cells of patients with AML (acute myeloid leukemia) and Hodgkin's lymphoma. Overexpression seems to block retinoic acid (RA)-mediated cell proliferation, differentiation, and apoptosis, contributing to tumorigenesis. Its expression pattern makes it an attractive target for immunotherapy. It is a membrane-bound protein, and it is thus a good target for TCR (T cell receptor)-T cells and anti-PRAME vaccines. Several clinical trials are ongoing and have demonstrated the clinical potential of targeting PRAME in melanoma, lung cancer and other solid tumors. Further studies into the functions of this protein will bring new clinical advances in cancer therapy.

Sequence

GLSNLTHVL

Species

Human

Supplied As

Liquid, 100 µl

Formulation

1 mM peptide in DMSO

Stability

At least one year at -80°C.

Storage

Upon first thaw, aliquot and store at -80°C. Avoid repeated freeze-thaw cycles.

Application

Stimulation of human PRAME-specific CD8⁺ T cells

Related Products

<i>Products</i>	<i>Catalog #</i>	<i>Size</i>
PRAME Peptide (425-433)	78991	100 µl
PRAME Peptide (394-402)	82307	100 µl

Version 042324